Literature DB >> 1950672

Cortical osteoclasts are less sensitive to etidronate than trabecular osteoclasts.

D Chappard1, M Petitjean, C Alexandre, L Vico, P Minaire, G Riffat.   

Abstract

Acute osteoporosis after spinal cord injury is related to an early increase in osteoclastic resorption. Healthy subjects subjected to bed rest similarly increase their osteoclast number in trabecular bone. Bisphosphonates possess a highly antiosteoclastic activity. The effects of a 120 day bed rest period, with or without etidronate therapy on cortical bone were measured in 15 subjects. Cortical thickness and cortical porosity were measured on transiliac bone biopsies taken before and after the bed rest period. Osteoclasts were detected histochemically and were counted with a semiautomatic image analyzer. Cortical thickness, cortical porosity, and cortical osteoclast number were not significantly modified in subjects submitted to bed rest alone. In the etidronate-treated patients, cortical bone mass parameters were also found to be unaffected, but the most striking feature was that the osteoclast number was unchanged. Trabecular osteoclasts, on the contrary, were increased in the untreated subjects (+95.2%) but decreased in the treated subjects (-78%). Bone cells may have heterogeneous responses according to their trabecular or cortical location. Cortical osteoclasts seem to be unaffected by etidronate therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1950672     DOI: 10.1002/jbmr.5650060704

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  9 in total

Review 1.  Advances in the understanding of myeloma bone disease and tumour growth.

Authors:  Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2010-03-11       Impact factor: 6.998

2.  Zoledronic acid administration failed to prevent bone loss at the knee in persons with acute spinal cord injury: an observational cohort study.

Authors:  William A Bauman; Christopher M Cirnigliaro; Michael F La Fountaine; LeighAnn Martinez; Steven C Kirshblum; Ann M Spungen
Journal:  J Bone Miner Metab       Date:  2014-08-27       Impact factor: 2.626

3.  Healing of a tibial double osteotomy is modified by clodronate administration.

Authors:  M T Nyman; T Gao; T C Lindholm; T S Lindholm
Journal:  Arch Orthop Trauma Surg       Date:  1996       Impact factor: 3.067

4.  Effects of risedronate on femoral bone mineral density and bone strength in sciatic neurectomized young rats.

Authors:  Jun Iwamoto; Azusa Seki; Tsuyoshi Takeda; Yoshihiro Sato; Harumoto Yamada
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

5.  Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study.

Authors:  H Rico; M Revilla; E R Hernández; L F Villa; M Alvarez de Buergo
Journal:  Calcif Tissue Int       Date:  1995-03       Impact factor: 4.333

6.  Clodronate increases the calcium content in fracture callus. An experimental study in rats.

Authors:  M T Nyman; P Paavolainen; T S Lindholm
Journal:  Arch Orthop Trauma Surg       Date:  1993       Impact factor: 3.067

7.  Recovery from pamidronate (APD): a two-year study in the dog.

Authors:  M D Grynpas; M Kasra; M Dumitriu; R Nespeca; J M Very; B P Mertz
Journal:  Calcif Tissue Int       Date:  1994-10       Impact factor: 4.333

Review 8.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

9.  Clinical efficacy and safety of pamidronate therapy on bone mass density in early post-renal transplant period: a meta-analysis of randomized controlled trials.

Authors:  Zijie Wang; Zhijian Han; Jun Tao; Pei Lu; Xuzhong Liu; Jun Wang; Bian Wu; Zhengkai Huang; Changjun Yin; Ruoyun Tan; Min Gu
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.